R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more
R&G PharmaStudies Co. Ltd. A (301333) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2022: 0.090x
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has a cash flow conversion efficiency ratio of 0.090x as of June 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.98 Million) by net assets (CN¥454.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
R&G PharmaStudies Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
R&G PharmaStudies Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HYAC-U
NYSE:HYAC-UN
|
-0.215x |
|
Daewoong
KO:003090
|
0.052x |
|
Selamat Sempurna Tbk
JK:SMSM
|
0.087x |
|
Piovan S.p.A
F:PV0
|
0.055x |
|
Thaifoods Group Public Company Limited
BK:TFG
|
0.178x |
|
BW Energy Ltd
OL:BWE
|
0.798x |
|
CLAROS MORT.TR.INC.DL-01
F:5WO
|
N/A |
|
Guangxi Nanning Waterworks Co
SHG:601368
|
0.033x |
Annual Cash Flow Conversion Efficiency for R&G PharmaStudies Co. Ltd. A (2019–2024)
The table below shows the annual cash flow conversion efficiency of R&G PharmaStudies Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.84 Billion | CN¥154.76 Million | 0.084x | -23.20% |
| 2023-12-31 | CN¥1.75 Billion | CN¥192.56 Million | 0.110x | +34.06% |
| 2022-12-31 | CN¥1.59 Billion | CN¥130.47 Million | 0.082x | -68.72% |
| 2021-12-31 | CN¥437.81 Million | CN¥114.57 Million | 0.262x | +99.97% |
| 2020-12-31 | CN¥336.98 Million | CN¥44.10 Million | 0.131x | -68.41% |
| 2019-12-31 | CN¥249.74 Million | CN¥103.48 Million | 0.414x | -- |